Načítá se...

Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery

Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmaceuticals (Basel)
Hlavní autor: Pardridge, William M.
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2020
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7697739/
https://ncbi.nlm.nih.gov/pubmed/33207605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13110394
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!